Summarize and humanize this content to 2000 words in 6 paragraphs in English
“The same concern applies to manufacturing equipment, which is all stainless steel,” she wrote.
The largest pharma companies warned through their European industry association, EFPIA, that pharma research, development and manufacturing is likely to be redirected toward the U.S., when they sat down for crisis talks with European Commission President Ursula von der Leyen this week.
But the group — conscious that interinstitutional negotiations are about to begin on a Brussels plan to overhaul landmark EU pharma legislation, and the industry’s existing lucrative patent protection with it — added that the migration could be put on hold if Europe “delivers rapid, radical policy change.”
That would mean “strengthening rather than weakening Europe’s intellectual property provisions,” the group said in an emailed statement, as well as “achieving a competitive EU market that attracts, values and rewards innovation in line with other economies at the forefront of patient care.”
Alexander Natz, secretary-general of Eucope, which represents mid-sized pharma companies, said: “Many of our members don’t have factories in the U.S. We can’t just build … within two months, factories in the U.S.”
Smaller and medium-sized pharma companies tend to have one or two innovative products, he said, and they “don’t have a product portfolio to say, ‘well, OK, I can level out the impact of the tariffs on product A, which is produced in that territory, by increasing sales potentially in product B.”
pl_facebook_pixel_args = [];
pl_facebook_pixel_args.userAgent = navigator.userAgent;
pl_facebook_pixel_args.language = navigator.language;
if ( document.referrer.indexOf( document.domain ) < 0 ) { pl_facebook_pixel_args.referrer = document.referrer; } !function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq( 'consent', 'revoke' ); fbq( 'init', "394368290733607" ); fbq( 'track', 'PageView', pl_facebook_pixel_args ); if ( typeof window.__tcfapi !== 'undefined' ) { window.__tcfapi( 'addEventListener', 2, function( tcData, listenerSuccess ) { if ( listenerSuccess ) { if ( tcData.eventStatus === 'useractioncomplete' || tcData.eventStatus === 'tcloaded' ) { __tcfapi( 'getCustomVendorConsents', 2, function( vendorConsents, success ) { if ( ! vendorConsents.hasOwnProperty( 'consentedPurposes' ) ) { return; } const consents = vendorConsents.consentedPurposes.filter( function( vendorConsents ) { return 'Create profiles for personalised advertising' === vendorConsents.name; } ); if ( consents.length === 1 ) { fbq( 'consent', 'grant' ); } } ); } } }); }
